A practical reference on MC1R: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-10-06 and is reviewed periodically as new material appears.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
Lyophilised melanotan-2 is comparatively robust when kept dry, cold and dark, and a desiccated powder stored at minus twenty degrees Celsius or below is generally expected to retain its chemical integrity for extended periods. In solution the peptide is far less stable, with degradation proceeding through oxidation of tryptophan and histidine residues, hydrolysis adjacent to the lactam bridge, and aggregation at higher concentrations. Repeated freeze-thaw cycling accelerates loss of the parent peak. Working aliquots are therefore prepared once, held cold, and used without letting the stock return to ambient temperature.
Quality assessment of research-grade peptide rests mainly on reversed-phase high-performance liquid chromatography for purity and on mass spectrometry for identity confirmation. A single main peak above a stated threshold, commonly ninety-eight percent by peak area, is the usual release criterion applied by suppliers. Independent analyses commissioned by laboratories and consumer organisations have repeatedly reported discrepancies between label claims and measured content, including truncated sequences, residual trifluoroacetate, and lower-than-declared peptide mass. Those findings do not establish that every supplier is unreliable, but they indicate that purity figures printed on a vial are claims requiring verification rather than settled facts.
Regulatory treatment varies by jurisdiction and has changed over time. In several countries the peptide is handled as an unapproved prescription medicine, and import or sale for human use is restricted, while elsewhere it falls under poisons or controlled-substance schedules. Enforcement activity against online vendors has been reported in Australia, New Zealand, the United Kingdom and the United States. Scholarly writing discusses melanotan-2 chiefly as an experimental tool and as a case study in unregulated peptide supply, and its precise legal position in any given country should be checked against current national schedules.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Free base; salt forms add to total mass |
| Molecular mass | About 1024 daltons | Calculated for the free base |
| Structural class | Cyclic heptapeptide | Contains D-phenylalanine and norleucine |
| Parent hormone | Alpha-melanocyte-stimulating hormone | Endogenous tridecapeptide of 13 residues |
| Receptor profile | Non-selective melanocortin agonist | Interacts with MC1R, MC3R, MC4R and MC5R |
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Identity testing for a synthetic peptide relies on several complementary methods. Reversed-phase high-performance liquid chromatography separates the target from related impurities and reports purity as a percentage of total peak area. Mass spectrometry confirms molecular mass and can reveal deletions or truncations. Amino acid analysis and peptide mapping provide sequence-level confirmation, while counter-ion content and residual solvents are measured separately. A purity figure alone does not establish identity, so a complete dataset combines chromatographic and spectrometric evidence.
Lyophilized peptide powder is generally stored frozen, protected from light and moisture. Tryptophan residues are susceptible to oxidation, and the lactam bridge can hydrolyze under strongly acidic or basic conditions. Solutions prepared for laboratory work degrade faster than dry powder, and repeated freeze-thaw cycles accelerate loss. Common practice is to aliquot solutions before freezing and to avoid alkaline buffers. Reported stability windows vary with concentration, buffer, and temperature, so exact shelf lives are method-specific rather than universal.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
Identification in laboratories relies on reversed-phase liquid chromatography coupled with tandem mass spectrometry, with product-ion spectra compared against a certified reference standard. High-resolution mass spectrometry supplies accurate mass confirmation, and peptide mapping after enzymatic digestion separates melanotan II from closely related analogues. Quantitation of seized material is complicated by unknown counter-ions and residual trifluoroacetate left from purification. Immunoassays raised against alpha-melanocyte-stimulating hormone can cross-react, so chromatographic confirmation is normally required. Urinary detection windows are short, and reported limits of detection differ substantially between laboratories.
Harrison, for his fundamental and far-reaching studies of protein structure using X-ray crystallography 2017 Titia de Lange, for her elucidation of the protection of telomeres and the maintenance of genome stability 2016 Susan Lindquist (posthum), in recognition of her pioneering work on the mechanisms of protein folding and the severe consequences of protein misfolding that are manifest in disease 2015 Yoshinori Ohsumi, in recognition of his pioneering discoveries of molecular pathways and biological functions of protein degradation by autophagy 2014 Frederick Alt, in recognition of his pioneering work in elucidating the mechanisms of genome rearrangements in immune and cancer cells 2013 Winfried Denk, David Tank and Watt W. Webb, in recognition of their invention of multiphoton fluorescence microscopy and its application to illuminating the function of brain microcircuits 2012 Stephen J. Elledge, for elucidating how eukaryotic cells sense and respond to DNA damage 2011 Nahum Sonenberg, for his transformative studies of the control of protein synthesis in mammalian cells 2010 C. David Allis and Michael Grunstein, for their discovery that histones and histone acetylation directly regulate transcription 2009 Jules Hoffman and Ruslan Medzhitov, for elucidating the mechanisms of innate immunity 2008 John Gurdon, Irving Weissman and Shinya Yamanaka, for their pioneering work in the field of stem cell research 2007 F.-Ulrich Hartl and Arthur L. Horwich, for their pioneering work in the field of protein-mediated protein folding 2006 Mary F.
== Discovery == The discovery of dye-ligand ability is from a blue dye called blue dextran. The blue dye is used as a void volume (V0) marker for a gel filtration column. It has shown that the dye has a property to bind to some certain proteins like pyruvate kinase and elute out with the void volume. Later on, it was found that "cibacron blue FG3-A", reactive dye link to dextran, is responsible for the interaction with the proteins.
The now elderly McCormick reunites with the also elderly Helen and asks her to marry him; she happily accepts, proving that true love does indeed last forever. McCormick introduces Nat to Helen, and the film ends with the three joining hands and going for a seaside stroll together.
Sources: en.wikipedia.org
== External links == Sophora flavescens Ait. Ya Ling, Jian; Ying Zhang, Guo; Jie Cui, Zhao; Kai Zhang, Chang (2007). "Supercritical fluid extraction of quinolizidine alkaloids from Sophora flavescens Ait. and purification by high-speed counter-current chromatography" (PDF). Journal of Chromatography A. 1145 (1–2): 123–127. doi:10.1016/j.chroma.2007.01.080. PMID 17289059. Krishna, Panthati Murali; Knv, Rao; S, Sandhya; Banji, David (2012). "A review on phytochemical, ethnomedical and pharmacological studies on genus Sophora, Fabaceae". Revista Brasileira de Farmacognosia. 22 (5): 1145–1154. doi:10.1590/S0102-695X2012005000043.
=== Proposed sovereign state === On 21 September 2024, it was reported that Prime Minister Edi Rama of Albania was planning to create the Sovereign State of the Bektashi Order, a sovereign microstate for the order within the Albanian capital of Tirana. Rama said the aim of the new state would be to promote religious tolerance and a moderate version of Islam.
Sherman leaves with Richmond and a tennis ball covered in the youth formula and heads to a presentation at Phleer Pharmaceuticals that Buddy is giving about the youth formula. Meanwhile, a worried Denise discovers what has happened and that Sherman's brain damage is progressing. With Cletus' help, Denise goes after him. Sherman takes advantage of the canine DNA crossed with Buddy's and throws the tennis ball to distract him. Buddy catches the ball in his mouth, and the youth formula transforms him back into a toddler, then further into a glowing mass of sentient genetic material. Sherman chases the genetic material, intent on drinking it to correct his condition. However, the material evaporates on the edge of a fountain before he can get to it. Cletus and Denise arrive too late to save him, and Denise breaks into tears, which hit the genetic material and fall into the fountain. As they go to leave, Sherman looks into the fountain, remarking that it is "pretty". Seeing the water is glowing, Denise realizes the genetic material has reconstituted thanks to her tears and that if Sherman drinks the fountain water before it dissipates, he will be restored to normal. Sherman drinks the water and is able to restore his genetic makeup to its proper order, restoring his intelligence. With Buddy Love defeated, Sherman and Denise finally get married. During the wedding reception, Sherman's older brother, Ernie Klump Sr., sings a song in honor of the couple, while Richmond continues to be hexed by the now normal-sized hamster.
Sources: en.wikipedia.org
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.
Melanotan-1, also called afamelanotide, is a linear analogue with greater selectivity for MC1R and has received approval in some jurisdictions for a specific photosensitivity disorder. Melanotan-2 is cyclic, less selective, and reaches central receptors more readily. The two are often confused in online discussion despite different pharmacology and regulatory status.
Alpha-MSH is an endogenous tridecapeptide derived from pro-opiomelanocortin. Melanotan-2 reproduces its core receptor-binding sequence inside a shortened, stabilised ring. The result is a molecule with a longer effective half-life and higher potency than the parent hormone.
Solutions are best kept cold, protected from light, and buffered to a pH that limits hydrolysis. Dividing a stock into single-use aliquots avoids repeated freeze-thaw cycles, which measurably reduce the intact parent peak over time.